These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 34056539)
1. Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. Araujo DV; Wang A; Torti D; Leon A; Marsh K; McCarthy A; Berman H; Spreafico A; Hansen AR; Razak AA; Bedard PL; Wang L; Plackmann E; Chow H; Bao H; Wu X; Pugh TJ; Siu LL JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34056539 [TBL] [Abstract][Full Text] [Related]
2. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Si H; Kuziora M; Quinn KJ; Helman E; Ye J; Liu F; Scheuring U; Peters S; Rizvi NA; Brohawn PZ; Ranade K; Higgs BW; Banks KC; Chand VK; Raja R Clin Cancer Res; 2021 Mar; 27(6):1631-1640. PubMed ID: 33355200 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB. He J; Kalinava N; Doshi P; Pavlick DC; Albacker LA; Ebot EM; Tukachinsky H; Pratt J; Fusaro G; Oxnard GR; Green G; Fabrizio D; Baden J J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38035725 [TBL] [Abstract][Full Text] [Related]
4. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954 [TBL] [Abstract][Full Text] [Related]
5. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131 [TBL] [Abstract][Full Text] [Related]
6. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Schenker M; Burotto M; Richardet M; Ciuleanu TE; Gonçalves A; Steeghs N; Schoffski P; Ascierto PA; Maio M; Lugowska I; Lupinacci L; Leary A; Delord JP; Grasselli J; Tan DSP; Friedmann J; Vuky J; Tschaika M; Konduru S; Vemula SV; Slepetis R; Kollia G; Pacius M; Duong Q; Huang N; Doshi P; Baden J; Di Nicola M J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39107131 [TBL] [Abstract][Full Text] [Related]
7. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC. Schuurbiers M; Huang Z; Saelee S; Javey M; de Visser L; van den Broek D; Heuvel MVD; Lovejoy AF; Monkhorst K; Klass D J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217576 [TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242 [TBL] [Abstract][Full Text] [Related]
9. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526 [TBL] [Abstract][Full Text] [Related]
10. Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings. Sturgill EG; Misch A; Jones CC; Luckett D; Fu X; Schlauch D; Jones SF; Burris HA; Spigel DR; McKenzie AJ Oncologist; 2022 Mar; 27(3):175-182. PubMed ID: 35274716 [TBL] [Abstract][Full Text] [Related]
11. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284 [TBL] [Abstract][Full Text] [Related]
12. Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB. Fridland S; Choi J; Nam M; Schellenberg SJ; Kim E; Lee G; Yoon N; Chae YK J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462324 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy. Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552 [TBL] [Abstract][Full Text] [Related]
14. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Kim ES; Velcheti V; Mekhail T; Yun C; Shagan SM; Hu S; Chae YK; Leal TA; Dowell JE; Tsai ML; Dakhil CSR; Stella P; Jin Y; Shames DS; Schleifman E; Fabrizio DA; Phan S; Socinski MA Nat Med; 2022 May; 28(5):939-945. PubMed ID: 35422531 [TBL] [Abstract][Full Text] [Related]
15. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L J Immunother Cancer; 2019 Apr; 7(1):98. PubMed ID: 30944026 [TBL] [Abstract][Full Text] [Related]
16. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999 [TBL] [Abstract][Full Text] [Related]
18. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer. Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313 [TBL] [Abstract][Full Text] [Related]
19. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036 [TBL] [Abstract][Full Text] [Related]
20. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer]. Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686 [No Abstract] [Full Text] [Related] [Next] [New Search]